Asgpr-binding compounds for the degradation of extracellular proteins
US-2024424108-A1 · Dec 26, 2024 · US
US10022450B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10022450-B2 |
| Application number | US-201615241221-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 19, 2016 |
| Priority date | Mar 8, 2013 |
| Publication date | Jul 17, 2018 |
| Grant date | Jul 17, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A chimeric toxin is disclosed comprising a peptide ligand specifically targeting neurons involved in pain processing; and a clostridial neurotoxin light chain, wherein the ligand is linked to the light chain. The methods of preparing such chimeric toxin and the method of using the chimeric toxin to regulate pain transmission are also disclosed.
Opening claim text (preview).
We claim: 1. A method for inhibiting pain transmission in a patient in need thereof, the method comprising the step of administering to said patient a formulation comprising an effective amount of a chimeric toxin of a chimeric toxin comprising (i) a peptide ligand specifically targeting neurons involved in pain processing, wherein the ligand is Substance P (SEQ ID NO:1); and (ii) a clostridial neurotoxin light chain, wherein the ligand is linked to the light chain to form a chimeric toxin, and wherein the chimeric toxin does not comprise a translocation domain. 2. The method of claim 1 , wherein the formulation is delivered into lumbar intrathecal puncture space. 3. The method of claim 2 , wherein the formulation is in a water based isotonic vehicle prepared freshly prior to the administration. 4. The method of claim 1 , wherein the effective amount is in the range of 5 to 10000 U typically delivered in a volume of 1 mL. 5. The method of claim 4 , wherein the effective amount is in the range of 0.005 to 1000 micrograms of the ligand. 6. The method of claim 5 , wherein the effective amount is 0.5 micrograms. 7. The method of claim 1 , wherein the pain arises from cutaneous injury and inflammation, musculoskeletal injury and inflammation, visceral inflammation or injury, peripheral nerve injury as caused by chemicals, metabolic disease, physical injury, and mixtures thereof.
for hormones {(for neuromediators C07K14/70571)} · CPC title
Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin · CPC title
containing a fusion with a toxin, e.g. diphteria toxin · CPC title
containing a localisation/targetting motif · CPC title
{Tachykinins, e.g.} Eledoisins {, Substance P}; Related peptides · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.